Phase-3 trial of Bharat Biotech’s Covaxin commences in AIIMS

The phase-three human clinical trial of indigenously developed anti-coronavirus vaccine candidate Covaxin began at the AIIMS here on Thursday with Dr M.V. Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose.

‘Covaxin’ is being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Dr Srivastava was the first one to receive the shot, which would be given to around 15,000 volunteers at the AIIMS over the next few days, sources said. PTI